NervGen Pharma: Expects to File Restated Audited Financial Statements for Year Ended Dec. 31, 2025, Including Restated 2024 Comparative Figure and Adjustment to Jan. 1, 2024, Opening Balances >NGEN

Dow Jones2026/09/25 20:35

By:Dow Jones

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

NASDAQ TRADE HALT CONTINUES <SVA.O> REASON NOT AVAILABLE AT 09:44 AM

Reuters•2026/10/01 13:44

US jobless claims data

Reuters•2026/10/01 12:41

ARITZIA INC. : CANACCORD GENUITY CUTS TARGET PRICE TO C$189 FROM C$193

Reuters•2026/10/01 12:32

AXOGEN, INC. : TRUIST SECURITIES CUTS TARGET PRICE TO $53 FROM $60

Reuters•2026/10/01 11:13